Usefulness of the C-Reactive Protein (CRP)-Albumin-Lymphocyte (CALLY) Index as a Prognostic Indicator for Patients With Gastric Cancer
The American Surgeon™ · 2024-11 · 90 (11) · 2703-2709
DOI: 10.1177/00031348241248693 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Surgeon™, online erschienen am 21.04.2024. Verfasst von Keigo Nakashima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, International University of Health and Welfare Hospital, Nasushiobara, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, C-Reactive Protein, Serum Albumin, Gastrectomy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: JSPS KAKENHI, Uehara Memorial Foundation, Japanese Foundation for Multidisciplinary Treatment of Cancer.
Abstract (Originalsprache)
Background
The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel immune nutrition scoring system associated with cancer prognosis. This study investigated the association between the CALLY index and the long-term outcomes of patients with gastric cancer.
Methods
We included 175 patients with gastric cancer who underwent curative gastrectomies at the Department of Surgery, International University of Health and Welfare Hospital between January 2011 and October 2019. The CALLY index was calculated based on the levels of serum albumin, serum CRP, and peripheral lymphocyte count. Utilizing both univariate and multivariate analyses, the prognostic value of the CALLY index was investigated.
Results
In the multivariate analyses, disease stage (hazard ratio [HR], 7.85; 95% confidence interval [CI], 3.31-18.6; P < .01), microvascular invasion (HR, 2.88; 95% CI, 1.30-6.36; P < .01), and low CALLY index (HR, 2.18; 95% CI, 1.00-4.76; P = .05) were independent and significant predictors of disease-free survival. Low body mass index (HR, 4.15; 95% CI, 1.63-10.6; P < .01), advanced disease stage (HR, 8.22; 95% CI, 3.47-19.5; P < .01), and low CALLY index (HR, 3.00; 95% CI, 1.3-6.93; P = .01) were independent and significant predictors of overall survival. The low CALLY index group had a lower body mass index ( P < .01), advanced disease stage ( P < .01), and a higher Glasgow prognostic score ( P < .01).
Conclusions
The CALLY index may be associated with a poor prognosis for gastric cancer, highlighting the utility of a comprehensive assessment using inflammatory, nutritional, and immunological statuses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, International University of Health and Welfare Hospital, Nasushiobara, Japan.
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Minato-ku, Japan.
ORCID-Profile: Koichiro Haruki
Förderung
- JSPS KAKENHI
- Uehara Memorial Foundation
- Japanese Foundation for Multidisciplinary Treatment of Cancer
Zitieren
APA
Nakashima, K., Haruki, K., Kamada, T., Takahashi, J., Tsunematsu, M., Ohdaira, H., Furukawa, K., Suzuki, Y., & Ikegami, T. (2024). Usefulness of the C-Reactive Protein (CRP)-Albumin-Lymphocyte (CALLY) Index as a Prognostic Indicator for Patients With Gastric Cancer. The American Surgeon™, 90(11), 2703-2709. https://doi.org/10.1177/00031348241248693
Vancouver
Nakashima K, Haruki K, Kamada T, Takahashi J, Tsunematsu M, Ohdaira H, et al. Usefulness of the C-Reactive Protein (CRP)-Albumin-Lymphocyte (CALLY) Index as a Prognostic Indicator for Patients With Gastric Cancer. The American Surgeon™. 2024;90(11):2703-2709. doi:10.1177/00031348241248693
BibTeX
@article{Nakashima2024,
author = {Nakashima, Keigo and Haruki, Koichiro and Kamada, Teppei and Takahashi, Junji and Tsunematsu, Masashi and Ohdaira, Hironori and Furukawa, Kenei and Suzuki, Yutaka and Ikegami, Toru},
title = {Usefulness of the C-Reactive Protein (CRP)-Albumin-Lymphocyte (CALLY) Index as a Prognostic Indicator for Patients With Gastric Cancer},
journal = {The American Surgeon™},
year = {2024},
volume = {90},
number = {11},
pages = {2703--2709},
doi = {10.1177/00031348241248693}
}
EUVIMED